Weight management medication

Weight management medication

Home » Weight management » Weight management medication

Last updated 23 September 2025:

The new weight management medication, Tirzepatide (also known as Mounjaro®) has been approved for NHS patients to support weight management.

NHS Staffordshire and Stoke-on-Trent has created a GP-led hub model across the county; eligible patients will be invited by prescribing hubs for assessment. This means those with the most urgent clinical need will be seen first, and you may have to wait until you are invited for assessment.

Please do not contact your GP, as they will not be able to assess your eligibility or prescribe you Mounjaro for weight management.

Eligibility criteria for Mounjaro

Following approval by NICE, tirzepatide (Mounjaro®) will be available on the NHS for eligible patients who meet the strict, nationally-set, criteria.  

Staffordshire and Stoke-on-Trent Integrated Care Board uses the NHS England-set criteria, which states that patients must have:

  • A BMI of 40 or higher (at the time of your assessment) or 37.5 or greater for individuals from certain ethnic backgrounds
  • Four more of these qualifying conditions:
    • hypertension (high blood pressure)
    • dyslipidaemia (abnormal levels of lipids in the bloodstream)
    • obstructive sleep apnoea (when your breathing stops and starts while you sleep)
    • cardiovascular disease (a general term for conditions affecting the heart or blood vessels)
    • type 2 diabetes (a common, chronic condition where the body doesn’t make enough insulin or the insulin it produces doesn’t work effectively, leading to high blood glucose levels).

Patients meeting the above criteria will be eligible for assessment to identify their suitability for Mounjaro. Eligible patients will be invited for assessment by primary care weight management hubs; patients with the most urgent clinical need being invited first.

Anyone not meeting this criteria will not be eligible for assessment in the first year of the drug being available to NHS patients. 

Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first, so this may mean you have to wait a little longer for an appointment, however it is our intention that anyone who meets the above criteria will have been invited for an assessment over the next 12 months. 

GP-led hubs created to assess patients’ eligibility

The service in Staffordshire and Stoke-on-Trent will be provided by General Practice ‘hubs’, this means you may be asked to attend a location that is not your normal GP practice but will still be accessible. GP practices have been asked to work together to ensure that you have better access to the specialist skills needed to deliver a holistic lifestyle assessment. The hubs will be managed by GPs from your local ‘primary care network (PCN)’ and your registered GP will be updated with all your progress and assessments. 

We recognise that a number of patients who have been taking the medication privately will be affected by the announcement of 14th August, outlining price increases to the Mounjaro injections. The NHS position still remains the same; we will only be offering the injection to those who meet the criteria set out above. Your GP will be able to support you with a conversation about managing your weight but will not be able to prescribe Mounjaro for weight management alone.  

If you are looking for support to help you manage your weight you can find useful information and resources on the ICS website at https://staffsstokeics.org.uk/local-weight-management-services/.

Patients with a complaint about this matter, should contact the Patient Advisory Liaison Services at patientservices@staffsstoke.icb.nhs.uk . 

Mounjaro and patient choice

NHS Staffordshire and Stoke-on-Trent is committed to giving patients greater choice and control over how they receive their health care, in line with the NHS Constitution and the NHS Choice Framework. 

Staffordshire and Stoke-on-Trent Integrated Care Board works with referrers, including GPs, to ensure they are aware of patients’ right to choose, and that appropriate information is available at the point of referral to ensure that an informed choice can be made. 

As set out in the NHS Constitution, you have a number of choices concerning care and treatment as a patient. These choices include but are not limited to: 

  • The right to choose which hospital or service to go to if your GP needs to refer you to see a specialist for a physical or mental health condition as defined in National Guidance 
  • The right to be involved in decisions about your healthcare and to be given the information you need to do this 
  • These are not the only choices you can make. There are choices in your lifestyle, decisions about your treatment, and even the way in which you interact with doctors and other health professionals that can all affect your health. 

Patients wishing to be prescribed Mounjaro will not be able to use their rights under the NHS Choice Framework; this is because the model for prescribing Mounjaro in Staffordshire and Stoke-on-Trent does not meet the criteria for patient choice.

To find out more please visit Your choices in the NHS – NHS (www.nhs.uk)

Oviva

We are aware that GPs are also still receiving enquiries about the availability of Oviva (Wegovy) in Staffordshire ad Stoke-on-Trent.

Staffordshire and Stoke-on-TrentT ICB does not commission a tier 3 weight management service from Oviva in Staffordshire and Stoke on Trent.  In line with NICE and NHSE guidance, weight management injections will be made available to eligible patients through a locally commissioned service from the end of June 2025.

Weight Management Services and Pregnancy / Contraception

Women taking medicines for weight loss and diabetes should continue to use effective contraception while taking these medicines, and in some cases for up to two months between stopping the medicine and trying to become pregnant. 

The Medicines and Healthcare products Regulatory Agency has warned that prescribed medication, such as Mounjaro, must not be taken during pregnancy, while trying to get pregnant or during breastfeeding. Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible. This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby. 

Effective contraception includes oral (the pill) and non-oral (the implant, coil or condoms) forms of contraception.

Mounjaro may reduce the effectiveness of oral contraceptives in those who are overweight. Those taking Mounjaro who are overweight and are using an oral form of contraceptive are advised to also use a non-oral form of contraception. This only applies to those taking Mounjaro, and is especially important for the four weeks after starting Mounjaro and after any dose increase. 

The full advice can be found on the regulator’s website. It comes after concerns from the UK regulator that some people are not using these medicines for weight loss and diabetes safely. 

Information for people accessing weight management medication outside the NHS

I am receiving weight management medication but want to get it through the NHS

If you have been prescribed weight management medication, but want to be prescribed through the NHS, you will need to be assessed to confirm you are eligible for Mounjaro, based on the criteria above.

Even if you are currently receiving weight management medication, but not prescribed by the NHS, you may have to wait to be called in for assessment. Patients whose clinical records show they may be eligible for assessment are being invited in to the new primary care weight management hubs for assessment to check they meet the eligibility criteria before being prescribed any medication.

I am thinking about accessing weight management medication, but not through the NHS

If you are considering accessing weight management medication, but are not eligible for NHS assessment or prescriptions, you will be responsible for providing your own clincical records to your provider. Your GP cannot provide them for you, but they can give them to you so you can pass them on. 

Can I refer myself to the weight management hub to be assessed?

No. The ICB’s weight management hubs are not a referral pathway. GPs will not be able to refer patients to the hubs; eligible patients will be invited to attend an assessment based on their medical records and who will have the most clinical benefit. Those most in need will be invited first.

Weight management medication Q&A

Below you will find the most commonly asked questions about weight management medication:

  • Can I access Mounjaro® now through the NHS?

    NHS Staffordshire and Stoke-on-Trent has developed a hub model to assess patients who meet the eligibility criteria for Mounjaro® and prescribe those suitable to be prescribed Mounjaro®. Patients with the most urgent clinical need will be invited for assessment by one of the hubs. 

  • I was being prescribed weight management injections privately but want to get them through the NHS. Can I?

    You will need to be assessed for eligibility by one of the GP-led hubs before you can be prescribed any weight management medication. 

  • I’ve been told I’m no longer eligible for Mounjaro®. Why?

    As part of your treatment, you will have regular reviews with your clinician or clinical team. Part of these reviews will include assessing your progress and reviewing your eligibility for the programme. Your eligibility may change as you progress through your weight management programme. Your clinician will explain your eligibility and alternative options if your eligibility for the programme changes. 

  • Can I get Mounjaro® prescriptions from my GP?

    GPs cannot prescribe Mounjaro® for weight management alone, but your GP may prescribe it for other health conditions, such as diabetes. If your health records show you may be eligible for Mounjaro®, you will be invited to attend a primary care weight management hub for assessment. 

  • What are the criteria for eligibility?

    The National Institute of Health and Care Excellence (NICE) published recommendations for Tirzepatide (Mounjaro®but recognised the need for a gradual approach to prioritise treatment for patients. NHS England (NHSE) developed qualifying criteria and patient groups who should be able to access the medication first. 

    Patients will be prescribed Mounjaro®® in cohorts with the following criteria: 

    Cohort 1 – Live from 23 June 2025, with services opening in Staffordshire and Stoke-on-Trent from Autumn 2025. Patients must have a BMI of 40* or more and have four or more of the five qualifying health conditions. 

    Eligible conditions for cohorts 1 to 3 are: 

    • hypertension (high blood pressure) 
    • dyslipidaemia (abnormal levels of lipids in the bloodstream) 
    • obstructive sleep apnoea (when your breathing stops and starts while you sleep) 
    • cardiovascular disease (a general term for conditions affecting the heart or blood vessels) 
    • type 2 diabetes (a common, chronic condition where the body doesn’t make enough insulin or the insulin it produces doesn’t work effectively, leading to high blood glucose levels). 

    Cohort 2 – Starting date TBC. In addition to patients in Cohort 1, the drug will also be offered to patients meeting the criteria for year 2 with a BMI of 35-39.9* and who have four of the five health conditions. 

    Cohort 3 – Starting date TBC.  In addition to patients in Cohorts 1 and 2, the drug will also be offered to patients meeting the criteria for year 3 with a BMI of 40* or more and having three of the five qualifying conditions. 

    The criteria mean those patients most in need of weight management medication will be able to receive it if they are eligible and want to have the injections. 

    *Due to an increased risk of health conditions in lower thresholds in these populations, the BMI applied to assess eligibility for Mounjaro® is set at 37.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds to ensure equitable clinical prioritisation and access to appropriate treatment. 

  • I meet the criteria; how do I get a prescription for Mounjaro® for weight management?

    You don’t need to do anything. The primary care weight management hubs which have been set up in Staffordshire and Stoke-on-Trent will be inviting patients in for assessment, and to confirm they are eligible for Mounjaro®. The hubs are a new service, with a limited number of places available for eligible patients, providing ‘wraparound’ support patients prescribed Mounjaro® must commit to as part of this weight management programme. Due to the limited number of places available, the service will be prioritising patients in the most urgent clinical need in year 1, with more spaces becoming available from June 2026 and April 2027. 

  • I meet the criteria for Mounjaro®, but don’t want to take medication or injections. What other options do I have to help me lose weight?

    You don’t have to have medication for weight management if you don’t want to. In Staffordshire and Stoke-on-Trent, there are a range of weight management services available locally. Details can be found on the ICS website, where you can find resources to support nutrition, healthy eating and diet advice, as well as exercise, books, podcasts as well as other online resources. Keep checking this page as we update the information from time to time. 

  • I am eligible for Mounjaro®; what ‘wraparound’ services are available as part of the programme?

    The services you will need will depend on where you live or where it is most convenient for you to access them. Your prescribing clinician will be able to advise you about the services you need, according to your personal circumstances and health needs. You can discuss your options if you are eligible for Mounjaro® following assessment.

  • Why do I have to wait to be assessed and prescribed Mounjaro®?

    The primary care weight management hubs are a new service, so there are a limited number of spaces available, with a nationally-set, limited budget available to support this weight management programme. Eligible patients with the most urgent clinical need will be invited for assessment, and if prescribed Mounjaro® will be treated first. 

  • Why won’t the ICB change the criteria for eligibility?

    The criteria is nationally-set by NHS England; this ensures everyone has fair and equal access to the medication, treatment and support they need, based on their clinical circumstances. Local health systems, such as the ICB, and providers, such as GPs, cannot change the criteria.  

    NICE has committed to reviewing access criteria after year 3 to evaluate the implementation and delivery of Tirzepatide. 

    Further details on the prioritisation of availability of Tirzepatide can be found in the NHS England Interim Commissioning Guidance for Tirzepatide. 

*Due to an increased risk of health conditions in lower thresholds in these populations, the BMI applied to assess eligibility for Mounjaro® is set at 37.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds to ensure equitable clinical prioritisation and access to appropriate treatment. 

For more information about alternative local weight management services, visit the ICS website – Local Weight Management services – Staffordshire and Stoke-on-Trent, ICS .